Overcoming sensitivity challenges in plasma-based neurology assays

James Freeman, SVP and Head of Core Lab Solution R&D, outlines the hurdles in neurology testing, emphasizing assay sensitivity, especially in the detection of biomarkers for conditions like Alzheimer's disease. Traditional testing relies on cerebrospinal fluid, but this requires invasive lumbar punctures. Siemens Healthineers is working to solve this by developing plasma-based assays that maintain high sensitivity, focusing on antibodies and antibody conjugates to improve detection. Special buffer formulations help reduce non-specific binding while enhancing signal strength. As researchers refine biomarkers such as p-tau 217*, advancements in plasma assays may revolutionize neurology diagnostics, making tests more accessible and effective in distinguishing disease markers from healthy populations.

*p-tau 217 assay is in development, Future availability cannot be guaranteed.